CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component

Near Add Your Location

Sorting 15 by

Memorial Sloan Kettering Cancer Center
New York, NY
  • Accepting patients
  • Show Principal Investigator
Perlmutter Cancer Center at NYU Langone Arena Oncology
North New Hyde Park, NY
  • Accepting patients
  • Show Principal Investigator
University of Nebraska Medical Center
Fred & Pamela Buffett Cancer Center
Omaha, NE
  • Accepting patients
  • Show Principal Investigator
John Theurer Cancer Center at Hackensack University Medical Center 
Hackensack Meridian Health
Hackensack, NJ
  • Accepting patients
  • Show Principal Investigator
University of Alabama at Birmingham
O'Neal Comprehensive Cancer Center
Birmingham, AL
  • Accepting patients
  • Show Principal Investigator
MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients
  • Show Principal Investigator
Tennessee Oncology - Hayes
Nashville, TN
  • Accepting patients
  • Show Principal Investigator
Roswell Park Cancer Institute
Buffalo, NY
  • Accepting patients
  • Show Principal Investigator
Beth Israel Deaconess Medical Center
Boston, MA
  • Accepting patients
  • Show Principal Investigator
Mayo Clinic (Arizona)
Phoenix, AZ
  • Accepting patients
  • Show Principal Investigator

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.